Dear Friends of BVGH:
As 2009 comes to an end, BIO Ventures for Global Health is excited about what lies ahead in the coming year. Each day, we see enthusiasm growing around the important role that biotech can play in solving some of the world’s most pressing health issues, and each day we work to convert that passion and enthusiasm to action. While we cherish the opportunity to work on life-saving issues, our focus on results reminds us that our actions must lead to commercially viable product development.
We took some important steps forward in 2009. We released two reports “Global Health Innovators: A Collection of Case Studies” and the 2009 edition of the “Global Health Primer.” We’ve moved incentives for research and development on drugs, vaccines, and diagnostics for the developing world ahead, particularly the FDA’s priority review voucher program. We have also made significant progress in the design of new research and development incentives for drugs for Chagas disease as well as point-of-care diagnostics. We also launched a Corporate Leadership Council to bring together biotech executives with an interest in global health, and debuted a new blog.
With these successes under our belt, here are just a handful of new projects we will be working on in 2010:
- Global Health Connect, a network that connects industry, nonprofits, governments, and the academic community to exchange expertise that will help in the creation of new products.
- Global Health Markets, a program that will help biotech companies navigate markets, supply chains, and processes and define exit strategies for global health products that differ from traditional pharmaceutical partnering models.
- 2010 Partnering for Global Health Forum, a meeting in conjunction with the BIO Annual Convention in May. Keep an eye out for an upcoming announcement.
- Diagnostics Innovation Map, a report that analyzes existing and upcoming diagnostic technologies that can be applied in the developing world.
- New Incentives Initiative, a program that helps biotech companies with the financial risk of developing new drugs, vaccines, and diagnostics for the world’s poor.
- A New and Improved Web site
Our goals for this year are ambitious, so we hope you will join us in making a commitment to ensure that we reach them. Your support is critical to our success. Please consider making a donation using the big red donation button below or by visiting our Web site.
Thank you for your support and best wishes for a happy new year,
Melinda Moree
CEO
